Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen.
about
Screening for prostate cancerScreening for prostate cancerScreening and early hormonal treatment of prostate cancer are accumulating strong evidence and support.Screening for prostate cancer: estimating the magnitude of overdetection.Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer.Current status of endocrine therapy in localized prostate cancer: cure has become a strong possibility.Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer.Multiple intracrine hormonal targets in the prostate: opportunities and challenges.PSA screening for prostate cancer: why so much controversy?Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial.Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial.Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.Prostate-specific antigen, clinical use and staging: an overview.Prostate disease: epidemiology, natural history and demographic shifts.European randomized study of prostate cancer screening: first-year results of the Finnish trial.
P2860
Q24201690-E6AAA86A-23CE-488E-8124-27AEB2C69444Q24245476-EB7F9F50-D082-467C-B1FE-CA3F942950FAQ33910607-8889B7EC-4BA3-4A24-A48B-2019D20F89D3Q34030152-5E3BB493-7545-449D-9A28-B01B9442411DQ34030359-A882A070-2B8E-4585-ABE8-10DC58AA4908Q35738188-243BAFA0-B2E5-4BFE-A5FE-7ED118F47FE0Q36039229-B03C6F8B-4A8D-47A0-B683-BA2698E96DD1Q36432836-AE2A0521-6FF0-43B7-A6B3-43D505E0FEB5Q36861779-ACBA847E-01AB-4358-B942-C19A89B30EB6Q37436987-48F89992-330B-4218-B85D-0DCB43DB4014Q39486360-8059D8F9-2107-4B18-A5B7-B7BDD21E7B13Q39589717-C88CB815-93F5-4C03-8BD3-69E0E91DF6FAQ39677100-5E327ADD-82CA-45E2-8E56-E6C7F1CD97EDQ39679696-A1896601-DD41-4111-9460-1362E5C2DC32Q39797810-41A203B8-604A-4720-9E89-B37B2360A7ABQ41409507-6FF05561-C9AC-4F49-B3F1-500F204E8809Q41450459-3D882BED-4776-421A-96BC-B54B47233EA4Q43201354-DAB79B83-B600-4A74-9681-635C39F6961C
P2860
Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Diagnosis of advanced or noncu ...... by prostate-specific antigen.
@en
Diagnosis of advanced or noncu ...... by prostate-specific antigen.
@nl
type
label
Diagnosis of advanced or noncu ...... by prostate-specific antigen.
@en
Diagnosis of advanced or noncu ...... by prostate-specific antigen.
@nl
prefLabel
Diagnosis of advanced or noncu ...... by prostate-specific antigen.
@en
Diagnosis of advanced or noncu ...... by prostate-specific antigen.
@nl
P2093
P1433
P1476
Diagnosis of advanced or noncu ...... by prostate-specific antigen.
@en
P2093
P304
P356
10.1016/S0090-4295(99)80419-1
P407
P577
1996-02-01T00:00:00Z